本文選題：動(dòng)脈粥樣硬化 + 麝香保心丸�。� 參考：《中藥新藥與臨床藥理》2015年04期

【摘要】：目的研究慢性炎癥反應(yīng)與動(dòng)脈粥樣硬化的關(guān)系及麝香保心丸防治動(dòng)脈粥樣硬化的作用機(jī)制。方法新西蘭雄性大耳白兔60只,隨機(jī)分為5組,即空白對(duì)照組,模型組,麝香保心丸低、高劑量組,立普妥組。高脂飼料造模4周后再連續(xù)給藥6周,末次給藥后(空腹大于12 h)耳動(dòng)脈采血,麻醉后取主動(dòng)脈,檢測(cè)血脂及炎癥因子,觀察各組動(dòng)物動(dòng)脈內(nèi)膜病理形態(tài)的改變,檢測(cè)Ca2+/鈣調(diào)蛋白依賴性蛋白激酶II(CaMKⅡ)蛋白表達(dá)及Ca MKII的活性。結(jié)果與模型組比較,麝香保心丸低、高劑量組及立普妥組的總膽固醇(TC)、甘油三酯(TG)、低密度脂蛋白膽固醇(LDL-C)、高密度脂蛋白膽固醇(HDL-C)、谷丙轉(zhuǎn)氨酶(ALT)、谷草轉(zhuǎn)氨酶(AST)、總膽紅素(TBIL)、直接膽紅素(DBIL)、腫瘤壞死因子α(TNF-α)、白細(xì)胞介素6(IL-6)、白細(xì)胞介素8(IL-8)水平及動(dòng)脈粥樣斑塊數(shù)量、厚度均有明顯降低,Ca MKII蛋白含量及活性均有明顯下降,差異均有統(tǒng)計(jì)學(xué)意義(P0.05,P0.01)。結(jié)論麝香保心丸具有抗實(shí)驗(yàn)性新西蘭大耳兔動(dòng)脈粥樣硬化的作用,并可能與降低CaMKⅡ蛋白含量或活性,減輕或抑制慢性炎癥反應(yīng)有關(guān)。
[Abstract]:Objective to study the relationship between chronic inflammation and atherosclerosis and the mechanism of Shexiang Baoxin Pill in preventing and treating atherosclerosis. Methods Sixty New Zealand male rabbits were randomly divided into 5 groups: blank control group, model group, low, high dose and Lipitor groups. After 4 weeks of high fat diet, the rats were given continuously for 6 weeks. After the last administration (fasting > 12 hours), the aorta was taken out, blood lipids and inflammatory factors were measured, and the pathological changes of intima of the arteries in each group were observed. The expression of Ca 2 / calmodulin dependent protein kinase II (CaMK 鈪，

本文編號(hào)：2038028